{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:34:54Z","timestamp":1787070894339,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>This retrospective study presents our single-institutional experience with stereotactic body radiotherapy for adrenal gland metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We evaluated patients with adrenal metastases treated by stereotactic body radiotherapy (SBRT) from 2014 to 2020. We performed an analysis of 35 patients. The median age of the patients was 62.2. Dosimetric parameters and treatment outcomes were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The primary diagnosis of the majority of patients was non-small cell lung cancer (94.3%). Treatment was performed in a median of 3 fractions, and the median prescribed dose was 24 Gy (range 22,5\u201327). The median follow-up was 17 months. Treatment response according to Response Evaluation Criteria in Solid Tumours was categorized as complete response in 11 patients, partial response in nine patients, stable disease in 7, and progressive disease in eight patients. Twenty seven patients had oligometastatic disease and treatment response. Patients with oligometastatic disease had a significantly higher rate of complete response and partial response to treatment than patients with common disease (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0,011). The 6-month and 1-year local control rates were 68.4% and 43%, respectively. In general, SBRT was well tolerated and no acute toxicities were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our retrospective study shows that SBRT can be applied safely in adrenal metastases with good results especially in patients with oligometastatic disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_891_21","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T09:25:21Z","timestamp":1681896321000},"page":"S47-S51","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy and outcomes of stereotactic body radiotherapy in adrenal gland metastases"],"prefix":"10.4103","volume":"19","author":[{"given":"Esra","family":"Kekilli","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taciser","family":"Demirkas\u0131mo\u011flu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"618","DOI":"10.3109\/0284186X.2011.652738","article-title":"Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases:A retrospective analysis of 34 patients","volume":"51","author":"Scorsetti","year":"2012","journal-title":"Acta Oncol"},{"key":"R2-20241021","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00268-001-0029-0","article-title":"Adrenal incidentaloma","volume":"25","author":"Brunt","year":"2001","journal-title":"World J Surg"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0002-9149(76)90316-7","article-title":"Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs","volume":"37","author":"Fowler","year":"1976","journal-title":"Am J Cardiol"},{"key":"R4-20241021","first-page":"1630","article-title":"Uncommon benign lesions of the adrenal glands mimicking sinister pathologies:Report of 8 cases","volume":"20","author":"Lykoudis","year":"2015","journal-title":"J BUON"},{"key":"R5-20241021","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3389\/fonc.2015.00185","article-title":"A retrospective review of cyberknife stereotactic body radiotherapy for adrenal tumors (primary and metastatic):Winthrop university hospital experience","volume":"5","author":"Desai","year":"2015","journal-title":"Front Oncol"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.ctrv.2014.04.001","article-title":"Surgical and ablative therapies for the management of adrenal 'oligometastases'- A systematic review","volume":"40","author":"Gunjur","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"217","DOI":"10.7785\/tcrt.2012.500320","article-title":"Stereotactic body radiation therapy for curative treatment of adrenal metastases","volume":"12","author":"Rudra","year":"2013","journal-title":"Technol Cancer Res Treat"},{"key":"R8-20241021","first-page":"291","article-title":"Stereotactic body radiotherapy for adrenal gland metastases:Single-center experience","volume":"34","author":"Yaprak","year":"2019","journal-title":"Turk J Oncol"},{"key":"R9-20241021","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/s13014-018-1152-5","article-title":"Short-term outcomes and clinical efficacy of stereotactic body radiation therapy (SBRT) in treatment of adrenal gland metastases from lung cancer","volume":"13","author":"Zhao","year":"2018","journal-title":"Radiat Oncol"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cncr.23209","article-title":"Aprospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions","volume":"112","author":"Milano","year":"2008","journal-title":"Cancer"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.ijrobp.2008.03.044","article-title":"Descriptive analysis of oligometastatic lesions treated with curative-intent stereotactic body radiotherapy","volume":"72","author":"Milano","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijrobp.2008.10.079","article-title":"Stereotactic body radiotherapy for treatment of adrenal metastases","volume":"75","author":"Chawla","year":"2009","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejca.2008.10.027","article-title":"Individual patient data analysis to assess modifications to the RECIST criteria","volume":"45","author":"Bogaerts","year":"2009","journal-title":"Eur J Cancer"},{"key":"R14-20241021","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.ijrobp.2011.06.181","article-title":"Stereotactic body radiotherapy vs. surgery for treatment of \u0131solated adrenal metastases:A matched pair analysis \u0131ncluding 62 patients","volume":"81","author":"Arnaud","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"7836","DOI":"10.1038\/s41598-020-64770-2","article-title":"Clinical efficacy of stereotactic body radiation therapy (SBRT) for adrenal gland metastases:A multi-center retrospective study from China","volume":"10","author":"Zhao","year":"2020","journal-title":"Sci Rep"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.radonc.2008.03.013","article-title":"Real-time tumor-tracking radiotherapy for adrenal tumors","volume":"87","author":"Katoh","year":"2008","journal-title":"Radiother Oncol"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.adro.2018.05.006","article-title":"Stereotactic body radiation therapy for adrenal gland metastases:Outcomes and toxicity","volume":"3","author":"Toesca","year":"2018","journal-title":"Adv Radiat Oncol"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4143\/crt.2016.057","article-title":"Minimally \u0131nvasive stereotactical radio-ablation of adrenal metastases as an alternative to surgery","volume":"49","author":"Franzese","year":"2017","journal-title":"Cancer Res Treat"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/COC.0b013e3182569189","article-title":"Stereotactic body radiotherapy in the treatment of adrenal metastases","volume":"36","author":"Ahmed","year":"2013","journal-title":"Am J Clin Oncol"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.adro.2017.07.011","article-title":"SBRT to adrenal metastases provides high local control with minimal toxicity","volume":"2","author":"Plichta","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13014-020-1480-0","article-title":"Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients","volume":"15","author":"K\u00f6nig","year":"2020","journal-title":"Radiat Oncol"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2217\/fon.10.165","article-title":"Stereotactic body radiation therapy for adrenal metastases:A retrospective review of a noninvasive therapeutic strategy","volume":"7","author":"Torok","year":"2011","journal-title":"Future Oncol"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"20200645","DOI":"10.1259\/bjr.20200645","article-title":"Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients","volume":"93","author":"Arcidiacono","year":"2020","journal-title":"Br J Radiol"},{"key":"R24-20241021","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1200\/JCO.2007.14.2091","article-title":"Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer:A systematic review and pooled analysis","volume":"26","author":"Tanvetyanon","year":"2008","journal-title":"J Clin Oncol"},{"key":"R25-20241021","first-page":"5285","article-title":"Robot-assisted extracranial stereotactic radiotherapy of adrenal metastases in oligometastatic non-small cell lung cancer","volume":"37","author":"Celik","year":"2017","journal-title":"Anticancer Res"},{"key":"R26-20241021","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.rpor.2015.05.009","article-title":"SBRT:A viable option for treating adrenal gland metastases","volume":"20","author":"Ippolito","year":"2015","journal-title":"Rep Pract Oncol Radiother"},{"key":"R27-20241021","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.prro.2016.09.005","article-title":"Stereotactic ablative radiotherapy for adrenal gland metastases:Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity","volume":"7","author":"Chance","year":"2017","journal-title":"Pract Radiat Oncol"},{"key":"R28-20241021","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00066-011-2192-z","article-title":"Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer","volume":"187","author":"Holy","year":"2011","journal-title":"Strahlenther Onkol"},{"key":"R29-20241021","first-page":"e1120","article-title":"Robotic radiosurgery for adrenal gland metastases","volume":"9","author":"Haidenberger","year":"2017","journal-title":"Cureus"},{"key":"R30-20241021","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1186\/s12885-020-07030-w","article-title":"Single-institutional outcome-analysis of low-dose stereotactic body radiation therapy (SBRT) of adrenal gland metastases","volume":"20","author":"Voglhuber","year":"2020","journal-title":"BMC Cancer"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_891_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:29Z","timestamp":1787067509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.jcrt_891_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_891_21","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2021-06-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}